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ABSTRACT 
Using a multiscale (dual resolution) approach combining an atomistic (GROMOS96) and 
coarse-grain (MARTINI) force field, we have been able to simulate the process of drug-
polymer nanoparticle assembly by nanoprecipitation from mixed solvents. Here we 
present the development and application of this method to the interaction of three 
poly(glycerol adipate) polymer variants with the anti-cancer drug dexamethasone 
phosphate. Differences in encapsulation efficiency and drug loading between the 
polymers are in agreement with the experimental trend. Reference atomistic simulations 
at key points along the predicted aggregation pathway support the accuracy of the much 
more compute-efficient multiscale methodology.  
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INTRODUCTION 
There is an increasing interest in nanomedicines due to the way that nanoparticles are 
handled physiologically within the body. Compared to conventional formulations, 
nanoparticles provide opportunities to exploit different barriers and uptake mechanisms 
to treat difficult diseases such as cancer1 and parasitic infections2. Research and 
development related to drug delivery technology is therefore becoming increasingly 
important for the pharmaceutical industry. Methodologies for encapsulation of drugs into 
micro and nanoparticles for use as drug delivery systems has been under development 
for at least two decades. A variety of different types of materials are used for drug 
encapsulation but mainly divide into lipid based technologies such as liposomes or solid 
lipid nanoparticles, and polymer based methodologies3. There are examples of liposome 
based nanoparticles which have been in clinical use for several years. But while drug 
encapsulation within polymeric nanoparticles has been achieved for a variety of 
polymers and small molecule drugs4–10, it is only recently that the first polymer based 
nanoparticle became clinically available3. This is important because the mechanisms of 
drug incorporation for the former are relatively easy to appreciate, but there is not a 
clearly understood mechanism for drug incorporation in the latter. It is these polymer 
based technologies which are of interest in this paper. 
There are a number of established methods for production of nanoparticles and 
incorporation of drugs11. Some of these processes have been investigated and analysed 
from a physicochemical viewpoint12 but these have not been modelled at a detailed 
level. Many of the nanoparticles produced have poor incorporation of drug and rapid 
drug release rates, where most delivery applications require high drug incorporation and 
slow release rates. Currently, improvements in encapsulation are dependent largely on 
trial and error to improve methodology and to introduce materials and excipients with 
different properties which may be beneficial for nanoparticle performance. Part of the 
problem with polymer nanoparticles is that we need to use processes which will both 
create the nanoparticle and simultaneously facilitate the incorporation of drug into that 
nanoparticle. The mechanisms of both of these aspects are poorly understood at a 
molecular level.  
Molecular simulation methods have the potential to provide insight into the fundamental 
processes at the atomic level that govern the emergent properties of a complex system 
at the macroscopic scale. However, until recently the computational expense of applying 
such techniques to the study of drug-polymer interactions has limited its application13,14. 
Samanta et al. have analysed the interactions of a single drug molecule with a few 
polymer chains15 and Ahmad et al. have simulated 20 drug molecules with 8 polymer 
chains in a single solvent16. Other papers have taken a mesoscale approach to 
modelling the polymers using dissipative particle dynamics17,18. This allows simulation of 
larger structures such as polymersomes19 but as these methods do not deal with the 
system at the atomic scale they a) limit our ability to draw on our understanding of the 
basic chemistry of intermolecular interactions to explain and predict behaviour and b) 
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limit the metrics that can be extracted from such simulations for comparison with 
experimental observables, such as spectroscopic properties. 
In the light of ever-increasing computational power, and new developments in simulation 
methods, it is timely to tackle this problem. We have chosen one particular drug-polymer 
assembly process, namely nanoprecipitation, which is widely used for nanoparticle 
preparation8. In this method droplets of a water-insoluble polymer in a water-miscible 
organic solvent were added to a large excess of water.  Drug can either be present in 
the organic polymer solution, or the aqueous receiving solution, depending on the drug 
properties. We have previously published work where the drug dexamethasone 
phosphate (DXMP) has been encapsulated into polymers based on poly(glycerol 
adipate) (PGA). PGA is synthesised using an enzymic method to produce a 
functionalised biodegradable polymer bearing pendant hydroxyl groups9. PGA may be 
flexibly modified by functionalization of some or all of its free hydroxyl groups to produce 
polymers with different physicochemical properties7,9. We have demonstrated that drug 
loading of DXMP into PGA is affected by polymer molecular weight and functionalization 
by acylation (both acyl chain length and percentage acylation). A partial functionalization 
by stearate (C18) was most effective for drug loading. The physicochemical 
rationalisation for these data is not obvious. While steroids such as cholesterol are 
known to intercalate with acyl lipid chains in biological membranes, the details of why 
and how a relatively polar steroid drug is encapsulated efficiently into a very hydrophobic 
polymer by the nanoprecipitation method are not obvious. 
Conceptually, nanoprecipitation involves a number of processes that will be somewhat 
interdependent in a complex way. Firstly there is the solvent diffusion process, whereby 
the water-miscible organic solvent disperses into bulk water, and water enters into the 
volume of the original droplet. This change in the solvent environment of the 
(hydrophobic) polymer triggers other processes; such as change in the polymer chains 
from an extended to a compacted conformation, intramolecular collapse, intramolecular 
aggregation and polymer chain entanglement. At the same time the drug molecules will 
be diffusing into the region around the polymer in response to a concentration gradient, 
modulated by their affinity for the various species present.  
Nanoprecipitation has been modelled previously, by Spaeth et al. using a single solvent 
type whose interaction parameters with the solutes were changed during the simulation 
to recreate the dispersion of acetone20. Some preliminary simulations we performed 
suggested that this method has some drawbacks, as the absence of a water/acetone 
solvent gradient across the simulated system changes its behaviour. Here we describe 
the development and application of a multiscale modelling method that explicitly includes 
this process. We find that by treating solvent-solvent and solvent-solute interactions in a 
coarse-grained manner, while maintaining atomistic resolution in modelling solute-solute 
interactions, we can achieve a balance between computational speed and accuracy (as 
benchmarked against fully atomistic simulations). This modelling investigates and 
recapitulates the established trends in the experimental data, and in the process gives 
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detailed insights into some of the factors, at the atomic scale, that influence 
encapsulation efficiency.  
METHODS 
Polymer designations 
The unmodified polymer is designated simply PGA100. Acylation of the pendant hydroxyl 
group with stearyl moieties is designated by C18PGA with a subscript to denote the 
percentage of monomers modified. 
Multiscale Model 
Our aim has been to model the time evolution of a system that begins as a spherical 
drop of a PGA polymer solution in acetone within a large box of water containing DXMP. 
To mimic the previously reported experimental conditions7,9 we calculated that a suitable 
fully atomistic model that contained all the relevant species would consist of a 12nm 
diameter droplet containing 16,000 molecules of acetone and two molecules of a PGA100 
30mer (or one molecule of PGA20-co-C18PGA80 or C18PGA100 30mer) at the centre of a 
60 nm3 box of c. 7 million molecules of water and 1270 molecules of DXMP. In total this 
would consist of over 21 million atoms.  Such a system would be at the limits of what is 
practical to simulate on even Tier0 computational resources and yet would only contain 
a single molecule of C18PGA100 polymer. To include more polymer molecules we would 
need a larger droplet of the organic solvent and a larger box of water to surround it. 
To address these issues we have taken advantage of the facility in the MD code 
GROMACS21 to use multiscale, dual-resolution, modelling methods. Water and acetone 
have been modelled as purely coarse-grained entities, using the MARTINI model and 
parameters22 . PGA and DXMP were modelled at both atomistic and coarse-grained 
levels, using the virtual sites approach23,24. Thus in our simulations all solute-solute 
interactions are treated fully atomistically, but solute-solvent and solvent-solvent 
interactions are treated using a coarse-grain force approach. While the modelled 
concentration of the drug in water is comparable to experiment at 3.22mg/ml, we have 
decreased the amount of acetone present in the system whilst increasing the polymer 
concentration to about four times the experimental value. This allowed us to observe 
how multiple polymer chains interact together to form a nanoparticle on a reasonable 
time scale (around 5 days on 192 cores). Increased concentrations were also used in 
similar work by Spaeth et al.20 Overall, we have thus been able to reduce the number of 
particles in the simulation system to 1,054,063 for two PGA20-co-C18PGA80 chains and 
1,053,653 for three PGA100 chains with 500 molecules of DXMP. 
Atomistic models, compatible with the GROMOS96 53a625 force field, for PGA, C18PGA 
and DXMP were generated using the automated topology builder (ATB)26. PGA100 
consists of 30 PGA monomers and PGA20-co-C18PGA80 consists of 4 PGA monomers 
with 26 C18PGA monomers evenly distributed throughout the polymer. 
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For the MARTINI force field22 the polymer has been modelled with 4 coarse grain (CG) 
sites per monomer. DXMP is modelled as 9 CG sites, because ring structures require a 
3 to 1 or lower mapping The CG beads were mapped on to the atomistic coordinates 
using VOTCA27 and converted to virtual sites. 
As per the standard MARTINI approach, four water molecules are represented by a 
single water bead and a single acetone molecule is represented by a single acetone 
bead. Details of the mapping and all non-standard parameters for the simulations are 
reported in the supplementary material. 
 
Simulation Parameters 
GROMACS version 4.6 was used for all production molecular dynamics. Simulations 
used periodic boundary conditions with Coulomb and van der Waals interactions shifted 
between 0 and the 1.2nm cut-off. The Berendsen barostat and v-rescale thermostat 
were used to equilibrate the system to 1 bar, 300K before a constant volume production 
run. Bonds were constrained using the LINCS algorithm to allow for a 2fs time step. 
Simulations were run for 80 ns with coordinates saved every 100ps. All simulations were 
repeated three times, starting from different, randomised, initial velocity distributions. 
Resolution Transformation 
As part of the simulation validation procedure (discussed below), at various points 11nm3 
sub-sections of the 50nm3 multiscale systems were converted back to fully atomistic 
representations. We used the backward python script28 to reintroduce atomistic detail to 
our coarse-grain solvent. Atomistic molecules (one for acetone and four for water) are 
placed in position of coarse-grain beads and subjected to energy minimisation and 
iterative molecular dynamics simulations with increasing time step up to 2fs. The original 
polymer, drug molecules with counter ions were reintroduced to the simulation box 
without their coarse-grain virtual sites to create a fully atomistic subsystem. 
Comparative analysis of multiscale and atomistic simulations 
Fully atomistic MD on these subsystems was run for 5 ns using the GROMOS96 53a6 
force field. A 2fs time step was used with all bonds constrained. Temperature and 
pressure were kept constant at 300K and 1 bar with the v-rescale thermostat and 
Berendsen barostat respectively. The particle mesh Ewald method was used for 
Coulomb interactions with a 1.2nm cut-off and van der Waals interactions were cut-off at 
1.2nm. For comparison, each 11nm3 sub-section was also simulated for 5 ns using the 
multiscale force field. 
The performance of the multiscale simulation vis-a-vie the atomistic “gold standard” MD, 
was analysed with regard to two key parameters. Firstly the time evolution of the total 
radius of gyration of the polymer clusters in the two simulations was compared using 
g_gyrate, and the autocorrelation function for this metric calculated using g_analyze. 
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Secondly the average orientation of the absorbed DXMP molecules with respect to the 
polymer nanoparticle was evaluated. For this we measured the difference in the distance 
of the phosphate and O3 oxygen atoms of DXMP from the polymer cluster centre of 
mass over the course of the simulation using g_dist (Figure 1). This was repeated for 
five different (randomly-selected by number) drug molecules and averaged. In addition 
the radial distribution of all DXMP molecules from the centre of mass of the polymer 
nanoparticle was calculated over the last 30ns of the simulation using g_rdf. 
Figure 1 Calculation of the orientational metric (Δ distance). 
 
Calculation of drug loading and encapsulation efficiency 
Experimentally polymer-based drug delivery systems are analysed for their ability to 
encapsulate drug molecules. There are a variety of experimental techniques used to 
discern the amount of drug that is encapsulated. For our simulations we have the luxury 
of being able to see exactly how many drug molecules make contact with the polymer 
nanoparticle when it has formed. 
The two most commonly used metrics for measuring drug encapsulation are 
encapsulation efficiency (EE) (Equation 1.1) and drug loading (DL) (Equation 1.2). 
Encapsulation efficiency will give an indication as to the amount of drug that was present 
in solution ends up encapsulated in the polymer nanoparticle. This value depends on the 
amount of drug present at the start of the simulation. If a small amount of drug was 
present in solution and it eventually all gets encapsulated on the surface of the polymer 
the EE is 100%. As such it can give values that may not give an accurate indication of 
the encapsulation ability of a polymer. 
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To alleviate this problem the DL is also calculated. DL is an indication of the total 
capacity for a polymer nanoparticle to encapsulate drug molecules. Ideally this value 
should be as large as possible to get the optimal delivery of drug from the polymer 
nanoparticle. However, DL is often very low for polymer-based drug delivery systems. 
EE for a polymer could be 100% yet the DL may still be low depending on the amount of 
drug present in solution at the start. In our simulations, a drug was considered bound to 
the nanoparticle if it made contact with it. !"#$%&'($)*+"!!""#$#%&$' = !!"##!!"!!"#$!!"!!"!#$"%&'()*!"#$%! "##!!"!!"#$!!"#$ !!!!!                     (1.1) !"#$!!"#$%&' = !!"##!!"!!"#$!!"!!"!#$"%&'()*!"#$%! "##!!"!!"!#$"%&'()* !!!!!!!!!!!!!!!!!!          (1.2) 
 
RESULTS and DISCUSSION  
Optimisation/Calibration of the Multiscale model 
The relative dielectric constant (εr) must be carefully chosen for any multiscale 
simulation. The εr specifies the strength of electrostatic interactions between molecules 
in the system, with high values of εr resulting in increased dampening of Coulombic 
forces. The MARTINI force field is designed to use εr = 15; however, the GROMOS96 
53a6 atomistic force field is calibrated to a value of 1. This results in difficult calibration 
for the multiscale model, which uses both force fields but must select one value of εr for 
the whole simulation. After extensive test runs we found that, with careful adjustment of 
the non-bonded CG virtual site interactions with the solvent molecules, excellent 
agreement between multiscale and reference atomistic simulations could be achieved 
using εr = 6 for the former. The effect of εr on simulation behaviour is discussed in more 
detail below. 
The MARTINI force field claims a 3-8 effective speed up over atomistic simulations22, 
mainly due to the loss of effective friction when using CG beads. To ensure that the rate 
of acetone dispersion, and subsequently the rate of polymer nanoprecipitation, was 
correct in the multiscale simulations, we carried out test MD simulations. Atomistic and 
coarse-grained models on mixed acetone/water systems showed that default MARTINI 
parameters underestimate the acetone diffusion coefficient (1.367x10-5 cm2/s by the 
Einstein relation, compared to 2.113 x10-5 cm2/s for the atomistic simulation). This 
contradicts the expected speed up in dynamics for CG molecules over their atomistic 
equivalents. Adjustments to the solvent intermolecular potentials (see supplementary 
data) resulted in excellent agreement with the atomistic diffusion coefficient (2.213 x10-5 
cm2/s for the multiscale system). 
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Simulation of PGA100 nanoprecipitation in the presence of DXMP 
 
Figure 2 Snapshots taken during the 80 ns multiscale simulation of PGA100 with DXMP. A: 5 ns (with 
acetone shown), B: 5 ns, C: 30 ns, D: 50 ns, E: 80 ns (with acetone shown), F: 80 ns. DXMP (multi), 
PGA (white), acetone (blue). For clarity water and coarse-grain virtual sites not shown. 
Using the simulation set-up in the Methods section (a droplet of a polymer in acetone 
solution within a box of an aqueous solution of DXMP), we first explored the 
nanoprecipitation of the parent, un-substituted, PGA100 over an 80 ns multiscale 
simulation. The polymer molecules in the acetone drop at the beginning of the simulation 
are initially well dispersed and in chain-extended conformations (Figure 3B). As the 
acetone disperses into the surrounding water, the relatively hydrophobic polymer chains 
move towards the centre of the shrinking droplet. Because the rate of diffusion of the 
polymer chains is slower than that of the solvents, they experience an increasingly polar 
environment and polymer-polymer interactions become more prominent. This produces 
both intramolecular collapse of individual polymer chains and stronger, more entangled, 
intermolecular interactions. DXMP binds to the polymer at the surface of the acetone 
drop as PGA100 is exposed in these regions to the surrounding water. Eventually enough 
acetone disperses to cause full aggregation of the polymer chains; at this point a 
proportion of DXMP molecules become encapsulated in the nascent nanoparticle 
(Figure 2D-F). 
Many of the features of this simulation are critically dependent on the nature and kinetics 
of the solvent exchange and dispersion process. It was originally assumed that acetone-
water equilibration of the droplet happens instantaneously, compared with polymer-
polymer dynamics preventing the need to simulate acetone dispersion. However, in 
preliminary simulations beginning with dispersed and extended polymer chains in pure 
water, polymer chains tended to undergo intramolecular collapse much more rapidly 
A 
B 
C 
D F 
E 
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than intermolecular aggregation, producing a very different form of granular material 
(results not shown). Simulations using a single solvent type whose characteristics were 
‘morphed’ with properties ranging from pure acetone to pure water over the course of the 
simulation, in a manner similar to Spaeth at al21, also produced much less entangled 
structures, because there is no retreating acetone/water interface to drive association 
(results not shown).  
Simulation of PGA20-co-C18PGA80 nanoprecipitation in the presence of DXMP 
 
Figure 3 Snapshots taken during the 80 ns multiscale simulation of PGA20-co-C18PGA80 with DXMP. 
A: 5 ns (with acetone shown), B: 5 ns, C: 30 ns, D: 50 ns, E: 80 ns (with acetone shown), F: 80 ns. 
DXMP (multi), PGA (white with C18 chains yellow), acetone (blue). For clarity water and coarse-grain 
virtual sites not shown. 
The aggregation of the PGA20-co-C18PGA80 polymer chains is subtlety different to that 
of the parent, un-functionalised PGA. The more hydrophobic carbon chains are sparingly 
soluble in acetone and are free to extend away from the polymer (Figure 3C). Towards 
the end of the simulation the polymer chains become more exposed to the water rich 
environment resulting in the carbon chains becoming buried in the emerging 
nanoparticle (Figure 3D-F). However due to the degree of side-chain functionalisation of 
this polymer there is insufficient PGA backbone to fully shield the hydrophobic C18 
chains from the surrounding water. This leaves hydrophobic chains exposed to interact 
with DXMP molecules at the surface (Figure 3F). 
Similarly to the PGA100 simulation, DXMP molecules that diffuse into the nascent 
nanoparticle bury their more hydrophobic groups in the C18/acetone phase keeping the 
hydrophilic phosphate group in the polar PGA backbone/aqueous phase (Figure 3). 
A 
B 
C 
D F 
E 
!! 10!
In practical formulation experiments, DXMP-loaded nanoparticles were found to display 
a 20% larger zeta potential than non-loaded polymer nanoparticles5. This finding is one 
indication that the simulation is consistent with wet-lab data and suggests the 
orientational preference of DXMP seen in these simulations – i.e. with the exposed 
phosphate groups at the surface of the nanoparticles, is a plausible explanation for the 
observed negative zeta potential in the experimental nanoparticles.  
Model Validation 
To assess the accuracy of our multiscale simulations a single fully atomistic simulation of 
the nanoprecipitation of the polymer was run and the aggregation of the polymer chains 
compared with the behaviour observed using the multiscale force field (Figure 4). In 
general the agreement is excellent, though the Rg decreases slightly faster using our 
multiscale force field and in addition the final nanoparticle is denser using the fully 
atomistic (GROMOS96) force field. This appears to be due to CG acetone lubricating 
polymer chains in the multiscale nanoparticle and so decreasing the particle’s density. 
!
Figure 4 The total radius of gyration for a two polymer cluster over a 50 ns nanoprecipitation 
simulation performed using a fully atomistic (light grey), or multiscale (dark grey) force field. 
To repeat all simulations at the fully atomistic level was computationally too costly, 
therefore to further compare these force fields, snapshots of manageable but 
representative sub-sections of the whole simulation system, centred on the nascent 
nanoparticle, were extracted at three time points (30, 50, and 80 ns)  from each 
multiscale simulation). We then used a procedure originally developed for multiscale 
biomolecular systems28 to re-introduce atomistic detail for the solvent molecules (see 
Methods). The behaviour of the polymer and drugs over 5 ns of (fully atomistic) 
molecular dynamics (MD) were then examined. For comparison, the same 
configurations of the same subsystems were also simulated for 5 ns using the original 
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multiscale parameterisation. As discussed above, two particular features of the 
simulations that seemed to be important for influencing encapsulation efficiency were the 
density of the nascent nanoparticle, and the orientational preferences of absorbed drug 
molecules. We evaluated the former by comparing the total radius of gyration of the 
nanoparticle in atomistic versus multiscale representations, and the latter using the 
orientational metric described in the Method section. 
 
Figure 5 Analysis for PGA100 (top) PGA20-co-C18PGA80 (bottom) with DXMP. Left: Two snapshots 
from the end of the 5 ns simulations using both atomistic and multiscale force fields. DXMP (multi), 
PGA (white with C18 chains yellow). Graphs for the total radius of gyration of the polymer cluster 
(middle) and the orientation of DXMP in relation to the centre of mass of the polymer chains (right). 
Atomistic (red), multiscale (green). 
Since we were studying sub-sections from a larger simulation, taken at non-equilibrated 
periods, we expected that, even over 5 ns, the simulations would show some temporal-
evolution in the chosen metrics. At the same time, the confinement of the system within 
a much smaller periodic box meant that its behaviour would probably differ to some 
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extent from that observed in the parent simulation. The key test was that atomistic and 
multiscale subsystems should behave equivalently as, indeed, was found to be the case 
(Figure 5).  Changes from the initial configurations were minor, and the degree and rate 
of change in each parameter was very similar between atomistic and multiscale models. 
The simulations started at 30 ns showed the greatest relaxation, presumably because 
they began from configurations that were furthest from equilibrium (Figure 5). 
Due to the short nature of these comparison simulations we wanted to analyse the 
autocorrelation function to ascertain how relaxed the polymer was during the simulations 
(Figure 6). 
!
Figure 6 The autocorrelation function for PGA100 (left) and PGA20-co-C18PGA80 (right) was calculated 
using the radius of gyration for the polymer in Fig 4. Atomistic (dark grey), multiscale (light grey). 
Due to the limited number of data points and replicas, the curves are noisy, but it can be 
seen that in general the relaxation rates of the polymer chains are broadly similar in the 
multiscale and fully atomistic simulations. 
 
Further Investigation of the Relative Dielectric Constant 
To assess the effects of the relative dielectric constant (εr) on the multiscale simulation 
we compared two additional multiscale simulations and one pure coarse-grain simulation 
against the 5 ns atomistic and multiscale simulations performed at the 50 ns time point 
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(Figure 7A). Our original multiscale simulation uses εr = 6; we tested the DXMP 
orientation and nanoparticle structure obtained using values of 1 and 15 and a pure 
coarse-grained model using εr = 15. 
With εr = 1 the DXMP has an orientation almost the opposite of that found in the 
atomistic and original multiscale (εr = 6) simulations. The phosphate head groups tend to 
be closer to the centre of mass of the nanoparticle than the oxygen atoms at the tail end 
of the molecule. This is not unexpected, because in the multiscale simulations the 
solvent is only modelled at the coarse-grained level and so does not have any 
electrostatic interactions. Our multiscale parameterisation increases the coarse-grained 
phosphate-water non-bonded interactions, which leads to a better approximation of 
atomistic behaviour. An increase of the dielectric constant to 15 allows the orientational 
preference of the absorbed drug to be predominantly maintained, but the reduction in the 
strength of all electrostatic interactions results in a generally flatter potential energy 
surface and orientational fluctuations become much more pronounced. 
 
Figure 7 A: Graph for the orientation of DXMP with respect to the polymer centre of mass in five 
different systems. Atomistic (red), multiscale (εr = 6) (green), multiscale (εr = 1) (blue), multiscale (εr = 
15) (pink), coarse-grain (εr = 15) (cyan). B: A snapshot taken at the end of the coarse-grain 
simulation. PGA20-co-C18PGA80 (white), DXMP (multi), brown spheres represent the phosphate 
group of DXMP. 
Perhaps surprisingly, the pure coarse-grained system, though lacking any atomistic 
solute-solute interactions, shows an orientation of DXMP that is very similar to that of the 
atomistic simulation, though with reduced fluctuations. However, while this single metric 
seems well satisfied, other aspects of the simulation are different from the atomistic 
standard such DXMP molecules aligning in an ordered crystal-like structure (Figure 7B). 
This result demonstrates the way in which the atomistic and coarse-grained aspects of a 
multiscale force field can interact in a complex way which is challenging to predict. 
Encapsulation Efficiency and Drug Loading 
Experimentally, PGA20-co-C18PGA80 nanoparticles have shown a higher DXMP loading 
and encapsulation efficiency than those based on PGA10. Our simulation results are in 
qualitative agreement with this trend: after running triplicates of both simulations we 
found an increase in encapsulation efficiency and drug loading between these two 
polymers (Table 1).  
Time%(ps)
Distance
(nm)
A B
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To test our model further we also simulated the encapsulation of DXMP by 100% C18 
esterified PGA. Experimentally a lower encapsulation efficiency is seen compared with 
PGA20-co-C18PGA8010. We found that our model also confirmed this experimental trend 
with a reduction in encapsulation efficiency and drug loading for C18PGA100 when 
compared with PGA20-co-C18PGA80 (Table 1). 
 Encapsulation 
Efficiency (%) 
% Change 
from PGA100 
Drug Loading 
(%) 
% Change 
from PGA100 
PGA100 5.93 +/- 0.25  44.76 +/- 1.05  
PGA20-co-C18PGA80  8.73 +/- 0.25 +47.2 46.60 +/- 0.71 +4.1 
C18PGA100  6.07 +/- 0.09 +2.4 34.16 +/- 0.35 -23.7 
     
Table 1 Encapsulation efficiency and drug loading for the three polymer systems is calculated for 
triplicate repeats. Data is obtained from the final snapshot of the simulation. 
The correlation between simulations and the experimental trends observed for drug 
incorporation provide mechanistic insight as to why PGA20-co-C18PGA80 is the most 
effective polymer at encapsulating DXMP. DXMP is amphiphilic (logP = 1.56) and can 
interact favourably with both the organic and aqueous phases in the system. From our 
simulations we observed that DXMP is surface active, with multiple molecules positioned 
at the surface of the shrinking acetone drop. As the drop reduces in size this brings the 
drug molecules towards the surface of the aggregating polymer chains. This drives the 
interaction of DXMP with the polymer nanoparticle. 
One advantage of using a computational model is that it can be quickly adjusted to test 
the new hypotheses. To further assess the effect of acetone dispersion on drug loading 
and encapsulation efficiency we ran a simulation of PGA20-co-C18PGA80 with DXMP in 
pure water without acetone. The polymer and drug molar ratios were kept the same as in 
the original multiscale simulation with acetone. We found a 23% reduction in the drug 
loading and 43% decrease in the encapsulation efficiency when compared to the original 
simulations using an acetone droplet. 
This result, albeit difficult to test experimentally, confirms our initial findings that acetone 
plays a major role in bringing drug molecules close to the surface of the polymer. A lack 
of acetone also results in faster polymer intermolecular collapse which prevents the 
polymer chains from interacting with DXMP. It also indicates that a drug molecule 
benefits from having interactions with both the acetone and water as this will allow the 
drug to be drawn towards the polymer as the acetone drop shrinks, increasing 
encapsulation efficiency and loading. 
The positioning of DXMP at the acetone drop surface could also explain why 
experimental work shows that this drug is encapsulated better than cytarabine by these 
polymers10. Cytarabine, with a log P of -2.8 and no charged groups may not show affinity 
for the acetone/water interface and hence may not be pulled into the surface of the 
aggregating nanoparticle to the same extent as the acetone droplet shrinks. 
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Figure 8 Metrics obtained from the 80ns nanoprecipitation simulations: (A) Number of DXMP 
molecules within 1.2nm of the polymer chains. (B) Radius of gyration of the all the polymers during 
the 10-80ns phase in the simulation. (C) The radial distribution functions of DXMP from the centre of 
mass of the polymer during the last 30ns of the simulation. Error bars are included (on A and B) for 
the standard error of the mean from triplicate repeats. PGA100 (red), PGA20-co-C18PGA80 (blue), 
C18PGA100 (green). 
The dispersion of acetone is consistent in all three systems yet we see differences in 
encapsulation efficiency i.e. the amount of drug that reaches the surface of the polymer 
nanoparticle. We analysed the interaction of the polymer chains with the drug molecules 
over the course of the 80 ns simulations (Figure 8A). Specifically we looked within the 
1.2nm cut-off for intermolecular interactions used in the simulations. 
 
As the acetone drop disperses, DXMP molecules are brought within the 1.2nm cut-off 
and they interact with the polymer chains. A saturation process is evident, and it is 
evident that PGA20-co-C18PGA80 is able to interact with more drug molecules than the 
other two polymers. 
Calculating the radial distribution of DXMP around the centre of mass of the polymer 
cluster during the last 30ns of the nanoprecipitation simulations also revealed similar 
results (Figure 8B). The PGA20-co-C18PGA80 nanoparticle has a larger number of drug 
molecules surrounding it than PGA100 or C18PGA100. 
To analyse these results further the total radius of gyration (Rg) for all the polymers was 
calculated during the 10-50 ns time period (Figure 8C). As acetone disperses the 
polymer is exposed to water and this triggers the aggregation of the polymer chains. 
PGA100 is most soluble in both acetone and water and so maintains the highest Rg during 
A 
B 
C 
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this time period. C18PGA100 is the most hydrophobic polymer, and it compacts most 
quickly and most extensively. We conclude therefore that the optimal drug loading 
properties of PGA20-co-C18PGA80 are a result of a balance between the possibility of 
favourable, hydrophobic, drug binding sites on the surface of the nanoparticle (favoured 
by increasing levels of acylation) and the degree of collapse, and so effective surface 
area, of the nanoparticle (favoured by decreased levels of acylation). 
These results are in agreement with contact angle measurements on similar PGA 
polymers by Orafai et al.29 A PGA60-co-C8PGA40 polymer showed the lowest surface 
free energy when compared with PGA100 and C8PGA100 polymers due to a balance of 
polar and nonpolar components. 
CONCLUSION 
A multiscale (dual resolution) modelling method has been used to simulate the 
encapsulation of DXMP by three related polymers. Detailed insights have been gained 
regarding the effects of acetone dispersion on the behaviour and interactions of drug 
and polymer molecules. DXMP molecules are surface active and show a preference for 
the retreating organic/aqueous interface of the dispersing drop of acetone. This results in 
the drug molecules being drawn towards the aggregating polymer chains within the 
shrinking acetone drop. An agreement with the experimental trend in encapsulation 
efficiency has been found for the three polymers tested. Our simulations show whilst 
C18 chains are required to interact favourably with DXMP having too many decreases 
solubility preventing the polymer from interacting with surrounding DXMP molecules. A 
balance between hydrophobic and hydrophilic moieties in the polymer seems to be 
important for optimal drug incorporation. 
In the absence of further experimental data to confirm details of our multiscale 
modelling, resolution transformation has been used to reintroduce atomistic detail to 
coarse-grain solvent. Fully atomistic simulations support the (relative) accuracy of the 
larger multiscale simulations. 
Our success here and the relative simplicity of the multiscale modelling method has 
encouraged us to apply the approach to the simulation of new PGA derivatives with 
other small molecule drugs, and should help facilitate the design of more efficient PGA 
drug delivery systems in the future. 
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SUPPORTING INFORMATION 
Details of the coarse-graining, and all non-standard force field parameters. This 
information is available free of charge via the Internet at http://pubs.acs.org/. 
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Force Field Parameters 
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Figure'1'Mapping'schemes'used'in'the'multiscale'force'field'and'the'bead'types'for'CG'interactions.'A:'PGA,'B:'C18PGA,'
C:'DXMP,'D:'Solvent'and'ions,'E:'PGA'termini. 
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Table 2 C6 and C12 values for the Lennard Jones potential for CG interactions used in the model; 
includes water, acetone and ion interactions with PGA, C18PGA and DXMP. 
Atom types and pair types for atomistic interactions are not changed from their defaults in 
the GROMOS96 53a6 force field. 
Atom%Type Atom%Type C6 C12 %%Na% GX% 1.50910E701 1.62670E703
%%P4% Na% 1.50910E701 1.62670E703 %%Na% HX% 1.33660E701 1.44080E703
%%Na% Na% 1.50910E701 1.62670E703 %%Na% IX% 1.33660E701 1.44080E703
%%P4% P4% 2.15580E701 2.32380E703 %%Na JX% 1.33660E701 1.44080E703
%%NA+% Na% 9.91670E702 1.06900E703 %%Na% KX% 1.33660E701 1.44080E703
%%NA+ P4 2.41450E701 2.60270E703 %%Na% LX% 1.33660E701 1.44080E703
%%P4% AX% 1.33660E701 1.44080E703 %%P4% AD% 1.16420E701 1.25490E703
%%P4% BX% 1.16420E701 1.25490E703 %%P4% BD% 8.62330E702 9.29530E704
%%P4% CX% 8.62330E702 9.29530E704 %%P4% CD% 8.62330E702 9.29530E704
%%P4% DX% 1.16420E701 1.25490E703 %%P4% DD% 8.62330E702 9.29530E704
%%P4% EX% 1.50910E701 1.62670E703 %%P4% ED% 8.62330E702 9.29530E704
%%P4% FX% 1.50910E701 1.62670E703 %%P4% FD% 1.33660E701 1.44080E703
%%P4% GX% 1.16420E701 1.25490E703 %%P4% GD% 1.33660E701 1.44080E703
%%P4% HX% 8.62330E702 9.29530E704 %%P4% HD% 1.50910E701 1.62670E703
%%P4% IX% 8.62330E702 9.29530E704 %%P4% ID% 2.41450E701 2.60270E703
%%P4% JX% 8.62330E702 9.29530E704 %%Na% AD% 1.50910E701 1.62670E703
%%P4% KX% 8.62330E702 9.29530E704 %%Na% BD% 1.33660E701 1.44080E703
%%P4% LX% 8.62330E702 9.29530E704 %%Na% CD% 1.33660E701 1.44080E703
%%Na AX% 1.50910E701 1.62670E703 %%Na% DD% 1.33660E701 1.44080E703
%%Na% BX% 1.50910E701 1.62670E703 %%Na% ED% 1.33660E701 1.44080E703
%%Na% CX% 1.33660E701 1.44080E703 %%Na% FD% 1.50910E701 1.62670E703
%%Na% DX% 1.50910E701 1.62670E703 %%Na% GD% 1.50910E701 1.62670E703
%%Na EX% 1.33660E701 1.44080E703 %%Na% HD% 1.50910E701 1.62670E703
%%Na FX% 1.33660E701 1.44080E703 %%Na% ID% 1.50910E701 1.62670E703
